Incorporation and performance verification of hepatic portal blood flow shunting in minimal and full PBPK models of liver cirrhosis
Patho‐physiological changes in liver cirrhosis create portacaval shunts that allow blood flow
to bypass the hepatic portal vein into the systemic circulation affecting drug …
to bypass the hepatic portal vein into the systemic circulation affecting drug …
A mechanistic pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions
Liver cirrhosis is a disease characterized by the loss of functional liver mass. Physiologically
based pharmacokinetic (PBPK) modeling was applied to interpret and predict how the …
based pharmacokinetic (PBPK) modeling was applied to interpret and predict how the …
After fifty years of hepatic clearance models, where should we go from here? Improvements and implications for PBPK modeling
KS Pang, WI Lu, GJ Mulder - Drug Metabolism and Disposition, 2024 - ASPET
There is overwhelming preference for application of the unphysiologic, well-stirred model
(WSM) over the parallel tube (PTM) and dispersion (DM) models to predict hepatic drug …
(WSM) over the parallel tube (PTM) and dispersion (DM) models to predict hepatic drug …
Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis
AN Edginton, S Willmann - Clinical pharmacokinetics, 2008 - Springer
Background: Liver cirrhosis is a progressive disease characterized by loss of functional
hepatocytes with concomitant connective tissue and nodule formation in the liver. The …
hepatocytes with concomitant connective tissue and nodule formation in the liver. The …
Exploring the pharmacokinetic mysteries of the liver: application of series compartment models of hepatic elimination
X Li, WJ Jusko - Drug Metabolism and Disposition, 2023 - ASPET
Among the basic hepatic clearance models, the dispersion model (DM) is the most
physiologically sound compared with the well-stirred model and the parallel tube model …
physiologically sound compared with the well-stirred model and the parallel tube model …
Hepatic impairment physiologically based pharmacokinetic model development: current challenges
AN Han, BR Han, T Zhang, T Heimbach - Current Pharmacology Reports, 2021 - Springer
Purpose This review summarizes the development processes of hepatic impairment (HI)
PBPK models, examines current challenges, and proposes potential solutions. Recent …
PBPK models, examines current challenges, and proposes potential solutions. Recent …
Does the systemic plasma profile inform the liver profile? Analysis using a physiologically based pharmacokinetic model and individual compounds
The physiologically based pharmacokinetic (PBPK) model for liver transporter substrates
has been established previously and used for predicting drug–drug interactions (DDI) and …
has been established previously and used for predicting drug–drug interactions (DDI) and …
Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model
Abstract Hepatic impairment (HI) moderately (< 5‐fold) affects the systemic exposure (ie,
area under the plasma concentration–time curve [AUC]) of drugs that are substrates of the …
area under the plasma concentration–time curve [AUC]) of drugs that are substrates of the …
Assessing liver-to-plasma partition coefficients and in silico calculation methods: when does the hepatic model matter in PBPK?
X Li, WJ Jusko - Drug Metabolism and Disposition, 2022 - ASPET
The primary models used in pharmacokinetics to assess hepatic clearance (CLh) are the
well-stirred model (WSM), the parallel tube model (PTM), and the dispersion model (DM) …
well-stirred model (WSM), the parallel tube model (PTM), and the dispersion model (DM) …
Modeling and simulation of hepatic drug disposition using a physiologically based, multi-agent in silico liver
L Yan, GEP Ropella, S Park, MS Roberts… - Pharmaceutical …, 2008 - Springer
Purpose Validate a physiologically based, mechanistic, in silico liver (ISL) for studying the
hepatic disposition and metabolism of antipyrine, atenolol, labetalol, diltiazem, and sucrose …
hepatic disposition and metabolism of antipyrine, atenolol, labetalol, diltiazem, and sucrose …